{"id":61128,"date":"2025-04-22T13:06:12","date_gmt":"2025-04-22T11:06:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/"},"modified":"2025-04-22T13:06:12","modified_gmt":"2025-04-22T11:06:12","slug":"concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/","title":{"rendered":"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology"},"content":{"rendered":"
\n

\nAgreement enables Bayer to leverage ConcertAI Translational360\u2122 and AI SaaS Solutions to leverage insights derived from AI and machine learning<\/i>\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360\u2122 and AI SaaS solutions, which use artificial intelligence and machine learning (AI\/ML)-derived insights to accelerate clinical development in precision oncology.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe agreement will fully leverage ConcertAI\u2019s newly launched Translational360\u2122, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network<\/a> of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.\n<\/p>\n

\nTranslational360\u2122 combines clinical, genomic, transcriptomic, and whole-slide imaging (WSI) from comprehensive molecular testing for deep phenotypical and genomic insights. Transcriptomics is increasingly a foundation of biopharma translational sciences, allowing researchers to understand disease molecular mechanisms, basis of patient response, and inter-patient variability that\u2019s essential for developing new therapeutics. Too often, clinical trial results in early phases are ambiguous with idiosyncratic positive and negative responses. The integrated data solutions and advanced AI enable selection of programs with the highest likelihood of success and design trials informed by multi-modal, multi-genomic, and transcriptomic data and AI.\n<\/p>\n

\n\u201cThis partnership furthers causal biological inferences where multi-modal and multi-molecular data can be integrated with AI\/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster,\u201d said Jeff Elton, Ph.D., CEO of ConcertAI. \u201cThis partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modeling of likely success and benefit, informing program priority and clinical study design.\u201d\n<\/p>\n

\n\u201cAs cancer rates continue to rise, we\u2019re committed to advancing next-generation solutions that can speed up drug discovery and clinical development, enabling us to bring precision oncology treatments to patients faster,\u201d said Sai Jasti, Head of Data Science and AI for Pharma R&D at Bayer. \u201cBy combining ConcertAI\u2019s powerful data solutions with Bayer\u2019s scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.\u201d\n<\/p>\n

\n\u201cMore AI-designed new molecular entities are progressing faster in first-in-human trials which is a great milestone,\u201d said Claudio D\u2019Ambrosio, Ph.D., Chief Revenue Officer of ConcertAI. \u201cOur entire R&D process has been historically built on studying controlled cell lines and animal models that don\u2019t reflect the interspecies differences, the physiology, and the different biological barriers we have in humans. We are flipping this paradigm on its head. We need to start with human cancer genomes and phenotypes and \u2018reverse translate.\u2019 Unlike only a few years ago, we now have powerful human data.\u201d\n<\/p>\n

\nAbout ConcertAI:<\/b>\n<\/p>\n

\nConcertAI is a leader in predictive and generative AI SaaS and multi-modal real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai<\/a>\u2122 technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon\u00ae provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ\u00ae is an initiative of ConcertAI, empowering oncology providers with ASCO-aligned automated QOPI and ASCO Certified\u00ae quality solutions and SmartLinQ\u2122 analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact
\n
<\/b>Treble<\/b><\/a>
McKenzie Covell
\n
<\/b>concertai@treblepr.com<\/b><\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Agreement enables Bayer to leverage ConcertAI Translational360\u2122 and AI SaaS Solutions to leverage insights derived from AI and machine learning CAMBRIDGE, Mass.–(BUSINESS WIRE)–ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360\u2122 and AI SaaS solutions, which use artificial intelligence and machine learning (AI\/ML)-derived insights to accelerate clinical development in precision oncology. The agreement … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61128","6":"format-standard","7":"category-industry"},"yoast_head":"\nConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Agreement enables Bayer to leverage ConcertAI Translational360\u2122 and AI SaaS Solutions to leverage insights derived from AI and machine learning CAMBRIDGE, Mass.–(BUSINESS WIRE)–ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360\u2122 and AI SaaS solutions, which use artificial intelligence and machine learning (AI\/ML)-derived insights to accelerate clinical development in precision oncology. The agreement ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T11:06:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250422295853\/en\/2443802\/22\/ConcertAI_Logo_Full_Color_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology\",\"datePublished\":\"2025-04-22T11:06:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/\"},\"wordCount\":604,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250422295853\\\/en\\\/2443802\\\/22\\\/ConcertAI_Logo_Full_Color_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/\",\"name\":\"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250422295853\\\/en\\\/2443802\\\/22\\\/ConcertAI_Logo_Full_Color_RGB.jpg\",\"datePublished\":\"2025-04-22T11:06:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250422295853\\\/en\\\/2443802\\\/22\\\/ConcertAI_Logo_Full_Color_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250422295853\\\/en\\\/2443802\\\/22\\\/ConcertAI_Logo_Full_Color_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/","og_locale":"en_US","og_type":"article","og_title":"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology - Pharma Trend","og_description":"Agreement enables Bayer to leverage ConcertAI Translational360\u2122 and AI SaaS Solutions to leverage insights derived from AI and machine learning CAMBRIDGE, Mass.–(BUSINESS WIRE)–ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360\u2122 and AI SaaS solutions, which use artificial intelligence and machine learning (AI\/ML)-derived insights to accelerate clinical development in precision oncology. The agreement ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/","og_site_name":"Pharma Trend","article_published_time":"2025-04-22T11:06:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250422295853\/en\/2443802\/22\/ConcertAI_Logo_Full_Color_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology","datePublished":"2025-04-22T11:06:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/"},"wordCount":604,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250422295853\/en\/2443802\/22\/ConcertAI_Logo_Full_Color_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/","url":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/","name":"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250422295853\/en\/2443802\/22\/ConcertAI_Logo_Full_Color_RGB.jpg","datePublished":"2025-04-22T11:06:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250422295853\/en\/2443802\/22\/ConcertAI_Logo_Full_Color_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250422295853\/en\/2443802\/22\/ConcertAI_Logo_Full_Color_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/concertai-announces-strategic-agreement-with-bayer-to-accelerate-clinical-development-in-precision-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61128"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61128\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}